Fifth Third Wealth Advisors LLC Sells 5,459 Shares of Zoetis Inc. $ZTS

Fifth Third Wealth Advisors LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 42.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,254 shares of the company’s stock after selling 5,459 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Zoetis were worth $913,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ZTS. CIBC Asset Management Inc boosted its holdings in Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after acquiring an additional 10,434 shares during the period. Mitsubishi UFJ Trust & Banking Corp increased its stake in Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after purchasing an additional 18,040 shares during the period. Ninety One UK Ltd lifted its position in shares of Zoetis by 19.6% during the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after purchasing an additional 183,686 shares during the last quarter. Quilter Plc lifted its position in shares of Zoetis by 10.2% during the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after purchasing an additional 40,615 shares during the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of Zoetis stock opened at $117.83 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock’s fifty day moving average price is $122.84 and its 200-day moving average price is $128.42. The firm has a market cap of $49.74 billion, a P/E ratio of 19.57, a P/E/G ratio of 1.79 and a beta of 0.98. Zoetis Inc. has a 12 month low of $113.29 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Analysts Set New Price Targets

ZTS has been the topic of a number of research analyst reports. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. UBS Group set a $136.00 price objective on shares of Zoetis in a report on Thursday, January 29th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Finally, Barclays began coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Zoetis presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.